Abstract:Transforming growth factor-b (TGF-b) was initially discovered by its ability to stimulate immortalized fibroblasts to grow in soft agar, a phenotype associated with expressing cancer-causing genes. Subsequently, it became clear that the ‘‘transforming activity’’ of TGF-b is reversible and can have potent cytostatic effects on normal epithelial cells. TGF-b is now well known for its dual effects in cancer progression; while TGF-b can have suppressive effects on normal and premalignant cells, more advanced cancer cells—frequently exposed to high levels of TGF-b produced by themselves or the stroma—are not only resistant to its cytostatic effects but also stimulated in their invasive and metastatic behavior. TGF-b can do this directly by facilitating epithelial tomesenchymal transition (EMT) and indirectly by acting on its surrounding stroma, promoting angiogenesis and immune evasion (Akhurst and Derynck, 2001). TGF-b signals via cell surface TGF-b type I and type II serine threonine kinase receptors and intracellular SMAD effector proteins. Upon TGF-b receptor activation, SMAD2 and SMAD3 become phosphorylated and form heteromeric complexes with SMAD4. These SMAD complexes can accumulate in the nucleus, where they act as transcriptional regulators. Because SMAD2 does not interact with DNA and the affinity of SMAD3 and SMAD4 for DNA is weak, there is a need for SMADs to partner with other DNAbinding transcription factors. The repertoire of SMAD interaction partners is large and diverse, providing a basis for multi-functionality of TGF-b and its context-dependent effects (Massagué, 2012). TGF-b receptors and SMADs are mutated in certain cancers. Inactivation of tumor suppressor genes, activation of proto-oncogenes, and microenvironmental changes can change the tumor suppressive and the tumor promoting activity of the TGF-b receptor/SMAD pathway. Most cancer patients die of metastasis and, because TGF-b is a strong driver of this process, TGF-b pathway inhibiting agents have been developed and tested in clinical trials. However, these compounds inhibit all TGF-b responses and may elicit unwanted effects. Careful selection of patients is warranted and proper biomarkers are needed to select those patients that will benefit from such systemic TGF-b-targeted therapy. A better understanding of the molecular mechanisms underlying the contextual effects of TGF-b in cancer may allow development of therapeutics selectively inhibiting its pro-oncogenic effects. Previously, Yu and colleagues provided some clues on these mechanisms by demonstrating that the phosphoserine/phosphothreonine-binding protein 14-3-3z, which is overexpressed in more than 40% of breast cancers, can potentiate TGF-b/ SMAD signaling during EMT and breast tumor progression (Lu et al., 2009). 14-33z and the tyrosine kinase receptor ErbB2 were found to cooperate in driving non-invasive ductal carcinoma in situ (DCIS) progression to invasive breast ductal carcinoma (IDC). Breast tumors expressing both ErbB2 and 14-3-3z have a higher incidence of metastasis than those expressing only one of them (Lu et al., 2009). In addition, they found 143-3z downregulated the cell cycle inhibitor p27 and activated phosphoinositide 3-kinase, thereby promoting cancer cell proliferation and survival (Rehman et al., 2014 and references therein).

C1orf106 (INAVA) Is a SMAD3-Dependent TGF-β Target Gene That Promotes Clonogenicity and Correlates with Poor Prognosis in Breast Cancer

C1orf106, an Innate Immunity Activator, is Amplified in Breast Cancer and is Required for Basal-Like/luminal Progenitor Fate Decision

TGFBI Protein High Expression Predicts Poor Prognosis in Colorectal Cancer Patients.

Nuclear Receptor NR4A1 Promotes Breast Cancer Invasion and Metastasis by Activating TGF-β Signalling

Identification and Characterization of a Novel Gene, C1orf109, Encoding a CK2 Substrate That is Involved in Cancer Cell Proliferation

ASF1b is a Novel Prognostic Predictor Associated with Cell Cycle Signaling Pathway in Gastric Cancer

Upregulation of INHBA Mediated by the Transcription Factor BHLHE40 Promotes Colon Cancer Cell Proliferation and Migration

TBLR1 is a Novel Prognostic Marker and Promotes Epithelial–mesenchymal Transition in Cervical Cancer

Low Transforming Growth Factor-β Pathway Activity in Cervical Adenocarcinomas

Molecular and Cellular Pathobiology NCOA 1 Directly Targets M-CSF 1 Expression to Promote Breast Cancer Metastasis

and TGF-β1 dependent gene expression biomarkers in conditional intestinal adenoma, organoids and colorectal cancer.

Cancer Cell Previews 14-3-3 z Turns TGF-b to the Dark Side

An AIB1 Isoform Alters Enhancer Access and Enables Progression of Early-Stage Triple-Negative Breast Cancer

TGFBR1*6A is a Potential Modifier of Migration and Invasion in Colorectal Cancer Cells.

The immune regulation and therapeutic potential of the SMAD gene family in breast cancer

TGF-β-induced MIR99AHG synergizes with PTBP1 to trigger a splicing switch of SMARCA1 that promotes invadopodia formation for metastasis in colorectal cancer

Integrative analysis of the canonical TGF?-Smad signaling pathway in breast cancer (Preprint)

Down-Regulation Of C9orf86 In Human Breast Cancer Cells Inhibits Cell Proliferation, Invasion And Tumor Growth And Correlates With Survival Of Breast Cancer Patients

Tgf-β1 transcriptionally promotes 90K expression: possible implications for cancer progression

Abl Interactor 1 Regulates Src-Id1-matrix Metalloproteinase 9 Axis and is Required for Invadopodia Formation, Extracellular Matrix Degradation and Tumor Growth of Human Breast Cancer Cells

Bromodomain 4 activation predicts breast cancer survival